Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for hard-to-treat prostate cancer: triple-drug combo enters human trials

NCT ID NCT07226986

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Nov 12, 2025 · Last updated May 21, 2026 · Updated 25 times

Summary

This study tests a new drug (AMO959) combined with a targeted radiation therapy (177Lu-PSMA-617) and a standard hormone therapy in men with a specific type of advanced prostate cancer (PSMA-positive mCRPC) that has stopped responding to initial hormone treatment. The goal is to see if the combination is safe and can shrink tumors or lower PSA levels. About 123 men will take part. This is an early-phase trial, so the main focus is safety and finding the right dose, not a cure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSMA-POSITIVE METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) WITH PRIOR EXPOSURE TO ONE PRIOR ARPI WHO ARE CANDIDATES FOR TAXANE-BASED CHEMOTHERAPY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Novartis Investigative Site

    RECRUITING

    Malvern, Victoria, 3144, Australia

  • Novartis Investigative Site

    RECRUITING

    Melbourne, Victoria, 3004, Australia

  • Novartis Investigative Site

    RECRUITING

    Murdoch, Western Australia, 6150, Australia

  • Novartis Investigative Site

    RECRUITING

    Clermont-Ferrand, 63011, France

  • Novartis Investigative Site

    RECRUITING

    Nantes, 44093, France

  • Novartis Investigative Site

    RECRUITING

    Essen, 45147, Germany

  • Novartis Investigative Site

    RECRUITING

    Sapporo, Hokkaido, 060-8648, Japan

  • Novartis Investigative Site

    RECRUITING

    Granada, Andalusia, 18014, Spain

  • Novartis Investigative Site

    RECRUITING

    Barcelona, 08036, Spain

  • Novartis Investigative Site

    RECRUITING

    Madrid, 28041, Spain

  • Rio Grande Urology

    RECRUITING

    El Paso, Texas, 79912, United States

    Contact

    Contact Email: •••••@•••••

  • Utah Intermountain Medical Center

    RECRUITING

    Murray, Utah, 84107, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

PSMA-POSITIVE METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) WITH PRIOR EXPOSURE TO ONE PRIOR ARPI WHO ARE CANDIDATES FOR TAXANE-BASED CHEMOTHERAPY